Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: Results of the HGG-2006 phase I/II trial

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 2033-2044

  Ardon, Hilko ^a   Van Gool, Stefaan W ^a   Verschuere, Tina ^a   Maes, Wim ^a   Fieuws, Steffen ^a   Sciot, Raf ^a   Wilms, Guido ^a   Demaerel, Philippe ^a   Goffin, Jan ^a   Van Calenbergh, Frank ^a   Menten, Johan ^a   Clement, Paul ^a   Debiec Rychter, Maria ^a   De Vleeschouwer, Steven ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Dendritic cell; Glioblastoma; Radiochemoimmunotherapy; Vaccine

Indexed keywords

CORTICOSTEROID; DENDRITIC CELL VACCINE; METOCLOPRAMIDE; SEROTONIN 3 ANTAGONIST; TEMOZOLOMIDE;

ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; BRAIN ABSCESS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPHAGIA; EPILEPTIC STATE; ESOPHAGITIS; FATIGUE; FEASIBILITY STUDY; FEMALE; FRAGILITY FRACTURE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMERUS FRACTURE; HYDROCEPHALUS; IMMUNE RESPONSE; INFECTION; INTESTINE ISCHEMIA; INTESTINE PERFORATION; LETHARGY; LEUKAPHERESIS; LEUKOPENIA; LUNG EDEMA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MYALGIA; NAUSEA; NEUROSURGERY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERIPHERAL EDEMA; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PRURITUS; SEIZURE; SEROUS OTITIS MEDIA; SHOULDER PAIN; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VACCINE PRODUCTION;

ADULT; AGED; BRAIN NEOPLASMS; CANCER VACCINES; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; STANDARD OF CARE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84870985481     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1261-1     Document Type: Article

References (40)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoom MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer EA, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987-996
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
3. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S (2010) Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study. J Neurooncol 99:261-272
4. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098-3104
5. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD (2009) An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8:2773-2779
6. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955-5964
7. Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, Wolff JE, Van Gool SW (2010) Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 54:519-525
8. De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JEA, Plets C, Sciot R, Van Gool SW (2004) Transient local response and persistent tumor control of recurrent malignant glioma treated with combination therapy including dendritic cell therapy. J Neurosurg (pediatrics) 100:492-497
9. Grauer OM, Wesseling P, Adema GJ (2009) Immunotherapy of diffuse gliomas: Biological background, current status and future developments. Brain Pathol 19:674-693
10. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515-5525
11. Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JEA, Kuhl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sorensen N, Opitz A, Van Gool SW (2004) Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91:1656-1662
12. Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S (2009) Dendritic cell therapy of high-grade gliomas. Brain Pathol 19:694-712
13. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C (2008) Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: Potential interaction with adjuvant chemotherapy. J Clin Neurosci 15:114-121
14. North RJ (1984) Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother 16:175-181
15. Emens LA (2010) Chemoimmunotherapy. Cancer J 16:295-303
16. Jameson SC (2002) Maintaining the norm: T-cell homeostasis. Nat Rev Immunol 2:547-556
17. Porter DL, June CH (2005) T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up! Bone Marrow Transplant 35:935-942
18. Banissi C, Ghiringhelli F, Chen L, Carpentier AF (2009) Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 58:1627-1634
19. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB (2008) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57:123-131
20. Park SD, Kim CH, Kim CK, Park JA, Sohn HJ, Hong YK, Kim TG (2007) Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 25:3485-3491
21. Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS, Hong YK (2010) Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 17:143-153
22. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P (2010) Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim Biophys Acta 1805:53-71
23. Wheeler CJ, Das A, Liu G, Yu JS, Black KL (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10:5316-5326
24. Liu G, Akasaki Y, Khong HT, Wheeler CJ, Das A, Black KL, Yu JS (2005) Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 24:5226-5234
25. Mirimanoff RO, Gorlia T, Mason W, van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563-2569
26. Ardon H, Verbinnen B, Maes W, Beez T, Van Gool S, De Vleeschouwer S (2010) Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination. J Immunol Methods 352:169-173
27. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME (2010) MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? Nat Rev Neurol 6:39-51
28. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38
29. Stummer W, Tonn JC, Mehdorn HM, Nestler U, Franz K, Goetz C, Bink A, Pichlmeier U (2010) Counterbalancing risks and gains from extended resections in malignant glioma surgery: A supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J Neurosurg 114:613-623
30. Muller AJ, Prendergast GC (2005) Marrying immunotherapy with chemotherapy: Why say IDO? Cancer Res 65:8065-8068
31. Nowak AK, Robinson BW, Lake RA (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63:4490-4496
32. Masucci GV, Mansson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J (2006) Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res 16:357-363
33. Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J, Fine HA (2009) Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial. J Clin Oncol 27:4155-4161
34. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16:2443-2449
35. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
36. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La CC, Sulman EP, Bekele BN, Aldape KD (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12:116-121
37. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189-4199
38. Clavreul A, Piard N, Tanguy JY, Gamelin E, Rousselet MC, Leynia P, Menei P (2010) Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas. J Clin Neurosci 17:842-848
39. Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G (2000) Adoptive immunotherapy in patients with recurrent malignant glioma: Preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9:e9
40. Wallenfriedman MA, Conrad JA, DelaBarre L, Graupman PC, Lee G, Garwood M, Gregerson DS, Jean WC, Hall WA, Low WC (1999) Effects of continuous localized infusion of granulocytemacrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor progression. J Neurosurg 90:1064-1071